Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC
February 16th 2023The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.
Read More
Yoga, Exercise Associated With Better Survival in Nonmetastatic Breast Cancer
December 7th 2022Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.
Read More
Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.
Read More
Radiotherapy Use in ATLAS Is Reflective of Current Guidance in High-Risk Localized Prostate Cancer
June 14th 2022Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.
Read More
Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL
June 3rd 2022Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.
Read More
Black Patients Less Likely to Participate on Clinical Trials in Breast Cancer
May 26th 2022Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.
Read More
Ibrutinib Plus Rituximab Confers Superior PFS to FCR in Previously Untreated CLL
December 13th 2021The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.
Read More
Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer
September 13th 2021Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.
Read More
Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials
September 13th 2021Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.
Read More
Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma
June 12th 2021Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.
Read More
Immuno-Oncology Therapies Could Be More Beneficiary for Small Cell Lung Cancer
January 28th 2021January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.
Read More
Nivolumab Improves Quality of Life in Patients with Esophageal/Gastroesophageal Cancer
January 15th 2021January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.
Read More